Last $0.02 USD
Change Today -0.0005 / -2.96%
Volume 506.5K
EAPH On Other Exchanges
As of 11:15 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

easton pharmaceuticals inc (EAPH) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/14 - $0.08
52 Week Low
12/22/14 - $0.0060
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

easton pharmaceuticals inc (EAPH) Related Businessweek News

No Related Businessweek News Found

easton pharmaceuticals inc (EAPH) Details

Easton Pharmaceuticals Inc., a specialty pharmaceutical company, designs, develops, and markets various topically delivered drugs and therapeutic health care products. Its products include Nauseasol, a motion sickness gel; Skin Renou HA, an anti-aging wrinkle cream using hyaluronic acid, which keeps the skin smooth; Kenestrin Gel used for arthritis, knees, elbows, shoulders, wrist, and back pain; Viorra, a hormone free, non-toxic, and topical gel that improves sexual functioning of women; and female sexual arousal disorder drug. The company is also developing XILIVE, an early stage cancer drug. In addition, it is involved in the medical marijuana business. The company was formerly known as LAM Industries, Inc. and changed its name to Easton Pharmaceuticals Inc. in March 2010. Easton Pharmaceuticals Inc. was founded in 1997 and is based in Toronto, Canada.

easton pharmaceuticals inc (EAPH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

easton pharmaceuticals inc (EAPH) Key Developments

Easton Pharmaceuticals Inc. Engages Kapadia Chartered Accountants Professional Corporation as Auditor

Easton Pharmaceuticals Inc. announced that it is engaging independent auditor Kapadia Chartered Accountants Professional Corporation. The company has provided a retainer and has formally engaged accredited Auditor Kapadia Chartered Accountants PC to perform an independent audit on the company's financial statements for the years ending 2013 and 2014 utilizing IFRS International Auditing Standard.

Easton Pharmaceuticals Provides AMFIL Update on the mPact - GROzone Antimicrobial System

Easton Pharmaceuticals Inc. announced update on the mPact - GROzone Antimicrobial System through its investment and ownership interest in AMFIL Technologies. Easton's partner AMFIL Technologies has updated the company and advised that the mPact - GROzone Antimicrobial Systems has received broad interest, is in discussions and has signed non disclosure agreements with the hopes to soon integrate other mPact - GROzone Antimicrobial Systems into a licensed large Canadian medical marijuana grow facility in Canada and into possibly another very large facility who has received a letter to build from Health Canada under the new MMPR system.

Easton Pharmaceuticals Announces Preparations for North American Product Launch

Easton Pharmaceuticals finalized and prepares for the launch of 3 initial OTC therapeutic products and other additional products for a marketing and sales launch. Easton has previously received all required ingredients and has readied 3 of its main OTC therapeutic products which are VIORRA TM, SKIN RENOU HA, and KENESTRIN GEL. The 3 products will be made immediately available once packaging is delivered which involves containers and labeling. Included with the 3 initial Easton products are an additional 3 cosmetic products as a result of an agreement with a Toronto, Canada based manufacturer who will manufacture and supply the U.S. and Canadian markets. The line of products will be formally announced in the next few short weeks which is expected to be in conjunction with a marketing plan and partner who have been in discussions with the company over the past month for U.S. and Canadian distribution. The new marketing partner will be replacing the previous agreement signed with Global Links following Easton's termination of the agreement originally signed in May of 2014. The missing packaging and labeling component is only expected to take 2 weeks for completion. Products are expected to be available for sale within the next 30 to 45 days in preparation for the upcoming Christmas buying season on Easton's website as well as multiple distributors as part of a comprehensive marketing strategy. Full details to be made shortly available. The initial products being launched, VIORRA TM, SKIN RENOU HA, and KENESTRIN GEL are expected to command a lucrative minimum gross margin of 40%-50% at a wholesale level, which is considered very conservative. Detailed retail pricing will be announced on launch date.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EAPH:US $0.02 USD -0.0005

EAPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EAPH.
View Industry Companies

Industry Analysis


Industry Average

Valuation EAPH Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EASTON PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at